Switch theme
Sign up to access all valuation multiples
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
2004
99
LTM Revenue $49.4M
LTM EBITDA $8.6M
$98.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
C-Rad has a last 12-month revenue (LTM) of $49.4M and a last 12-month EBITDA of $8.6M.
In the most recent fiscal year, C-Rad achieved revenue of $48.4M and an EBITDA of $9.3M.
C-Rad expects next 12-month revenue of XXX and NTM EBITDA of XXX
See C-Rad valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $49.4M | XXX | $48.4M | XXX | XXX | XXX |
| Gross Profit | $32.6M | XXX | $33.3M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $8.6M | XXX | $9.3M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $7.6M | XXX | $7.3M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $5.3M | XXX | $5.8M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, C-Rad's stock price is SEK 33 (or $3).
C-Rad has current market cap of SEK 1.1B (or $114M), and EV of SEK 958M (or $98.8M).
See C-Rad trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $98.8M | $114M | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, C-Rad has market cap of $114M and EV of $98.8M.
C-Rad's trades at 2.0x EV/Revenue multiple, and 10.7x EV/EBITDA.
Equity research analysts estimate C-Rad's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
C-Rad has a P/E ratio of 21.4x.
See valuation multiples for C-Rad and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV (current) | $98.8M | XXX | $98.8M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.6x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 13.0x | XXX | 13.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.4x | XXX | 19.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 40.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialC-Rad's last 12 month revenue growth is 8%
C-Rad's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
C-Rad's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
C-Rad's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for C-Rad and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 28% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
C-Rad acquired XXX companies to date.
Last acquisition by C-Rad was XXXXXXXX, XXXXX XXXXX XXXXXX . C-Rad acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was C-Rad founded? | C-Rad was founded in 2004. |
| Where is C-Rad headquartered? | C-Rad is headquartered in Sweden. |
| How many employees does C-Rad have? | As of today, C-Rad has 99 employees. |
| Who is the CEO of C-Rad? | C-Rad's CEO is Ms. Cecilia de Leeuw. |
| Is C-Rad publicy listed? | Yes, C-Rad is a public company listed on STO. |
| What is the stock symbol of C-Rad? | C-Rad trades under CRAD B ticker. |
| When did C-Rad go public? | C-Rad went public in 2007. |
| Who are competitors of C-Rad? | Similar companies to C-Rad include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of C-Rad? | C-Rad's current market cap is $114M |
| What is the current revenue of C-Rad? | C-Rad's last 12 months revenue is $49.4M. |
| What is the current revenue growth of C-Rad? | C-Rad revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of C-Rad? | Current revenue multiple of C-Rad is 2.0x. |
| Is C-Rad profitable? | Yes, C-Rad is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of C-Rad? | C-Rad's last 12 months EBITDA is $8.6M. |
| What is C-Rad's EBITDA margin? | C-Rad's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of C-Rad? | Current EBITDA multiple of C-Rad is 11.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
